Summary

For patients with active psoriatic arthritis (PsA), treatment with secukinumab at subcutaneous doses of 300 and 150 mg confers rapid and clinically significant improvement in signs, symptoms, physical function, and quality of life with no unexpected safety findings. This article reports on the results of the Efficacy at 24 Weeks With Long-Term Safety, Tolerability, and Efficacy Up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis [FUTURE 2; NCT01752634].